ACADIA Pharma (ACAD) - Narx-foyda koeffitsiyenti
ACADIA Pharmaceuticals (ACAD) kompaniyasining joriy P/E koeffitsiyenti konsolidatsiya bosqichini namoyish etmoqda, bunda parametr qiymati 8.80 ga yetmoqda. Ushbu tendentsiya generik dori vositalaridan daromadlarni himoya qiluvchi patent eksklyuzivligi bilan qo'llab-quvvatlanmoqda. Barqarorlik uzoq muddatli opsionlar bilan rag'batlantirilgan neyrobiologlarning kuchli jamoasi tomonidan ta'minlanadi. Pul oqimi sug'urta fondlari va Medicare davlat dasturlari orqali Parkinson kasalligi davolash vositalarining sotuviga asoslangan.
ACADIA Pharmaceuticals Inc (ACAD) boʻyicha keng qamrovli koʻrsatkichlar kesimi va tahlil
- narx va narxlar bo'yicha konsensus prognoz:
- bozor kapitallashuvi ko'rsatkichlari:
- balans bo'yicha xususiy kapital ma'lumotlari:
- qarzlar va to'lov qobiliyati haqida ma'lumot:
Umumiy qarzning kapitalga nisbati koeffitsiyenti ACADIA Pharmaceuticals|ACAD - Uzoq muddatli qarzning kapitalga nisbati|Qisqa muddatli qarzning kapitalga nisbati ACADIA Corp|ACAD - Kompaniyaning umumiy qarzi|Qarzning sof aktivlarga nisbati ACADIA Pharmaceuticals Inc.|ACAD - Kompaniyaning uzoq muddatli qarzi|Qisqa muddatli majburiyatlar ACADIA Pharmaceuticals|Oraliq qoplash koeffitsiyenti acadia-pharm.com
- sof foyda va baholash koeffitsiyentlari ma'lumotlari:
ACAD - Sof foyda|Prognoz qilingan kelajakdagi foyda ACADIA Pharmaceuticals|ACAD - Narxning foydaga nisbati|Kelajakdagi narx-foyda multiplikatori ACADIA Pharma|ACAD - Narxning foydaga va o‘sish sur’atiga nisbati|Korxona qiymatining foizlar, soliqlar va amortizatsiyadan oldingi foydaga nisbati koeffitsiyenti ACADIA Pharmaceuticals Inc.|ACAD - EBITDA operatsion foydasi|Bir aksiya uchun sof foyda (EPS TTM) ACADIA Pharmaceuticals|ACAD - Bir aksiya uchun sof foyda (EPS TTM)|So'nggi 12 oy davomida bir aksiya uchun sof foydaning yillik o'sishi acadia-pharm.com|ACAD - Joriy yilda foyda o'sishi|Keyingi yilda bir aksiya uchun sof foydaning kutilayotgan o'sishi ACADIA Pharmaceuticals
Kompaniyaning umumiy tahlili:acadia-pharm.com - ACAD
ACADIA Pharmaceuticals (ACAD) uchun ushbu koeffitsient biznesning bozor qiymatini uning sof foydasiga nisbatan aks ettiradi va aktivning premiumini baholash imkonini beradi. Kompaniyaning P/E koeffitsientini tahlil qilish orqali investor joriy kapitalizatsiyani Nuplazid patenti bo'yicha nizolar va Daybue xarajatlariga tegishli moliyaviy barqarorlik bilan solishtirishi, natijada aktivning qadrsizlanganini yoki operatsion xarajatlar fonida ortiqcha kutishlar xavfini aniqlashi mumkin.
Raqobatdosh kompaniyalar tahlili
P/E multiplikatori biogen.com|P/E multiplikatori NBIX|Narx-foyda koeffitsiyenti Regencell Bioscience Ltd RGC|P/E multiplikatori AXSM (Axsome Therapeutics Inc)|P/E multiplikatori Xenon Corp XENE|Viking Therapeutics - P/E multiplikatori|SUPN (supernus.com) - Narx-foyda multiplikatori|CPRX: P/E multiplikatori|DNLI - Biznesning o‘zini qoplash muddati|HRMY (Harmony Pharma) - P/E multiplikatori|P/E multiplikatori Biohaven Corp|Narx-foyda koeffitsiyenti AMLX (Amylyx Pharmaceuticals)|TRVI (trevitherapeutics.com) - Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati Praxis Precision Medicines, Inc. PRAX|AVXL (Anavex) - Kapitalizatsiyaning sof foydaga nisbati|CeriBell Corp - P/E multiplikatori|Kompaniya qiymatining sof foydaga nisbati PRTA (Prothena Corporation)|ALEC: P/E multiplikatori|annexonbio.com (ANNX) - P/E multiplikatori|Narxning foydaga nisbati Omeros Corp|NGNE: Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati AC Immune Corp (ACIU)|Narx-foyda koeffitsiyenti Voyager Corp VYGR|P/E multiplikatori NMRA (Neumora Therapeutics)|P/E multiplikatori scilexholding.com SCLX|Tevogen Bio - P/E multiplikatori|Alpha Cognition (ACOG) - Narx-foyda koeffitsiyenti|CGTX: P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati Inhibikase Pharma (IKT)|Narx-foyda koeffitsiyenti SAVA|P/E multiplikatori Assertio Therapeutics|Narx-foyda koeffitsiyenti COYA (Coya Therapeutics, Inc.)|Bozor narxining sof foydaga nisbati VTGN|P/E multiplikatori OVID (Ovid Therapeutics)|Biznesning o‘zini qoplash muddati Acumen Pharmaceuticals, Inc (ABOS)|CervoMed Inc. - P/E multiplikatori|Alterity Therapeutics (ATHE) - Narx-foyda koeffitsiyenti|CLNN: P/E multiplikatori|PepGen (PEPG) - P/E multiplikatori|Narxning foydaga nisbati Jupiter Neurosciences|Narxning foydaga nisbati RLMD|Narxning foydaga nisbati Annovis Bio, Inc. (ANVS)|Biznesning o‘zini qoplash muddati gracetx.com|P/E multiplikatori AIFF (Firefly Neuroscience)|P/E multiplikatori ANEW Medical KLTO|NeuroSense Therapeutics, Ltd. - P/E multiplikatori|Reviva Pharmaceuticals, Inc. (RVPH) - Narx-foyda koeffitsiyenti|MTVA: P/E multiplikatori|neuraxis.com (NRXS) - P/E multiplikatori|HSDT (Helius Medical Technologies, Inc.) - P/E multiplikatori|Narx-foyda multiplikatori PASG (Passage Bio Corp)|Narxning foydaga nisbati Neuphoria Therapeutics Inc. (NEUP)|Minerva - Narx-foyda multiplikatori|P/E multiplikatori ATHA (Athira Pharma, Inc.)|addextherapeutics.com (ADXN) - Kapitalizatsiyaning foydaga nisbati|ALZN: Narx-foyda koeffitsiyenti|CYCN - P/E multiplikatori|protagenic.com (PTIX) - Narxning foydaga nisbati|Pasithea Therapeutics Corp. - Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati Cortigent Inc|Kapitalizatsiyaning foydaga nisbati avenuetx.com ATXI|P/E multiplikatori BCLI|P/E multiplikatori Cara Therapeutics Inc. (CARA)|P/E multiplikatori CHRO (Chromocell Therapeutics Corporation)|ELYM - Narx-foyda koeffitsiyenti|Intra-Cellular - P/E multiplikatori|LBPH - P/E multiplikatori|MRNS: P/E multiplikatori|Narx-foyda multiplikatori NKGN|NRBO (NeuroBo) - P/E multiplikatori|Sage Therapeutics Inc (SAGE) - Biznesning o‘zini qoplash muddati|P/E multiplikatori SNPX|P/E multiplikatori trevena.com (TRVN)|Vigil Neuroscience, Inc. - Narx-foyda koeffitsiyenti|Kompaniya qiymatining sof foydaga nisbati WENA|CERE - Narxning foydaga nisbati
